Literature DB >> 22338019

The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?

Michael A Postow1, Margaret K Callahan, Jedd D Wolchok.   

Abstract

Ipilimumab has shown an overall survival benefit in 2 randomized phase III studies. A minority of patients achieve long-term disease control, highlighting the potential of this immunotherapeutic approach. In ongoing efforts, investigators are continuing to characterize these patients' unique clinical courses and correlate their responses with underlying mechanisms of antitumor immunity. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22338019     DOI： 10.1158/1078-0432.CCR-12-0409

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  13 in total

Review 1.  Immunomodulatory therapy for melanoma: ipilimumab and beyond.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Clin Dermatol       Date:  2013 Mar-Apr       Impact factor: 3.541

Review 2.  Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.

Authors:  Claire Vanpouille-Box; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

3.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.

Authors:  Claire Vanpouille-Box; Julie M Diamond; Karsten A Pilones; Jiri Zavadil; James S Babb; Silvia C Formenti; Mary Helen Barcellos-Hoff; Sandra Demaria
Journal:  Cancer Res       Date:  2015-04-09       Impact factor: 12.701

Review 4.  In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.

Authors:  Claire Vanpouille-Box; Karsten A Pilones; Erik Wennerberg; Silvia C Formenti; Sandra Demaria
Journal:  Vaccine       Date:  2015-07-03       Impact factor: 3.641

5.  Negative correlations of psychological distress with quality of life and immunotherapy efficacy in patients with advanced NSCLC.

Authors:  Ziran Bi; Wen Li; Jie Zhao; Lulian Pang; Yanyan Jing; Xiuqing Zhang; Senbang Yao; Xiangxiang Yin; He Zuo; Huaidong Cheng
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

Review 6.  The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation.

Authors:  Sandra Demaria; Karsten A Pilones; Claire Vanpouille-Box; Encouse B Golden; Silvia C Formenti
Journal:  Radiat Res       Date:  2014-06-17       Impact factor: 2.841

Review 7.  Checkpoint modulation in melanoma: an update on ipilimumab and future directions.

Authors:  David B Page; Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 8.  At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok
Journal:  J Leukoc Biol       Date:  2013-05-10       Impact factor: 4.962

Review 9.  Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).

Authors:  Sadek Malas; Micaela Harrasser; Katie E Lacy; Sophia N Karagiannis
Journal:  Oncol Rep       Date:  2014-06-20       Impact factor: 3.906

Review 10.  Predictors of clinical response to immunotherapy with or without radiotherapy.

Authors:  Susan M Hiniker; Holden T Maecker; Susan J Knox
Journal:  J Radiat Oncol       Date:  2015-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.